Trevi Therapeutics (TRVI) said Thursday that enrollment in its phase 2b study of investigational therapy Haduvio in idiopathic pulmonary fibrosis with chronic cough has reached 75% of the targeted sample size of 160 patients.
The company said an independent data monitoring statistician reaffirmed the sample size of 160 IDF patients with chronic cough following a sample size re-estimation analysis, wherein 80 participants were treated with Haduvio at the highest dose of 108 mg twice daily for six weeks.
Topline results from the trial are still expected in H1 2025, the company added.
Trevi's stock surged 71% in recent Thursday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。